LSD-induced Hallucinogen Persisting Perception Disorder with depressive features treated with reboxetine: case report
by
Lerner AG, Shufman E, Kodesh A, Kretzmer G, Sigal M.
Lev Hasharon Mental Health Medical Center,
Pardessya, POB 90000, Netanya, 42100, Israel.
lerneram@internet-zahav.net
Isr J Psychiatry Relat Sci 2002;39(2):100-

ABSTRACT

We would like to present the case of a patient who had a prior history of cannabis, ecstasy (MDMA) and LSD abuse and who developed both Hallucinogen Persisting Perception Disorder (HPPD) and a major depressive episode. Following two unsuccessful SSRIs trials, reboxetine was prescribed. During a six-month follow-up period on reboxetine 6 mg./day, no exacerbation of the visual disturbance or recurrence of the depressive features were reported. Reboxetine may have an alpha 2 adrenoreceptor modulating effect on both noradrenaline and serotonin release, thus reboxetine's alpha 2 adrenoreceptor modulating effect on noradrenaline release may affect sympathetic activity and be involved in the recovery process.

LSD
Efficacy
Reboxetine
NARIs versus SSRIs
Reboxetine v fluoxetine
Reboxetine: product info
Reboxetine and the elderly
Reboxtine versus fluoxetine (Prozac)
Reboxetine and the alpha2-adrenergic/5-HT1a receptors

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family